Rayvio_News_Filter
$SUNI 🏥
Sun Pharmaceutical Industries Limited announced that UNLOXCYT (cosibelimab-ipdl) was elevated to an NCCN Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Selected from hundreds of headlines